The Nasdaq Composite index fell on Wednesday, dragged down by losses in Amazon and Apple, while gains in healthcare stocks propped up the Dow and the S&P 500.
Amazon fell more than 5 percent after reports that President Donald Trump is looking to target the company by changing its tax treatment.
Apple dropped 0.68 percent after Goldman Sachs analyst cut sales estimate for iPhone for March and June quarters, citing weak demand.
However, Facebook’s shares rose more than 2 percent after the company said it was giving users more control over their privacy by making data management easier and redesigning the settings menu.
The social network has lost more than $100 billion in market value since March 16, when it first acknowledged that user data had been improperly harvested by a consultancy firm.
Broader markets have suffered this month on a back-and-forth between the United States and China on tariffs and fears of rising interest rates. The main indexes are on track for their worst month since January 2016.
Comments from top officials in the United States and China had given a sense that both the countries would negotiate over President Donald Trump’s move to impose tariffs on Chinese goods.
China is predictable to soon declare a list of retaliatory tariffs on US exports, its state-run Global Times stated on Wednesday.
At 2:35 p.m. ET, the Dow Jones Industrial Average was up 14.10 points, or 0.06 percent, at 23,871.81 and the S&P 500 dropped 2.91 points, or 0.11 percent, at 2,609.71.
The Nasdaq Composite was down 44.95 points, or 0.64 percent, at 6,963.85.
The S&P healthcare index was up nearly 2 percent on gains in Allergan, Celgene and Incyte.
Tesla dropped about 8.62 percent after the U.S. government said it would investigate a fatal crash and vehicle fire of a Model X in California. (Source: Reuters)
Stock in Focus: Biocept Inc (NASDAQ: BIOC)
Biocept Inc (NASDAQ: BIOC) has grabbed attention from the analysts when it experienced a change of 0.38% in the current trading session to trade at $0.32. A total of 5,507,423 shares exchanged hands during the intra-day trade contrast with its average trading volume of 2.57M shares, while its relative volume stands at 3.08. Relative volume is the comparison of current volume to average volume for the same time of day, and it’s displayed as a ratio. If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. If RVOL is above 2 it is In Play and this is more evidence Investors ought to be in the name. When stocks are *very* In Play one can see a RVOL of 5 and above. The higher the RVOL the more In Play the stock is.
Day traders strive to make money by exploiting minute price movements in individual assets (usually stocks, though currencies, futures, and options are traded as well), usually leveraging large amounts of capital to do so, therefore they trade on Stocks in Play. In Play Stocks are volatile enough to produce good risk and reward trading opportunities for both bull and bear traders intraday. Most company stocks have very little volatility. They generally move extremely slowly and they only produce big price swings when the company produces good or bad trading results, which may only happen a couple of times a year at best.
In deciding what to focus on – in a stock, say – a typical day trader looks for three things: liquidity, volatility and trading volume. Liquidity allows an investor to enter and exit a stock at a good price (i.e. tight spreads, or the difference between the bid and ask price of a stock, and low slippage, or the difference between the predictable price of a trade and the actual price). If a stock does not have good liquidity then it may take some time before a broker is able to negotiate a deal to buy or sell a stock and the broker may not be able to get the sell or buy price that the trader is looking for. This is a problem for day traders and it could mean the difference between a profitable and non-profitable trade.
Traders have different rules for what constitutes liquidity and a good guide is the volume of trades and volume of shares that are traded each day. 100,000 shares traded per day would be a minimum for most traders and some require 1,000,000.
Trading volume is a gauge of how many times a stock is bought and sold in a given time period (most commonly, within a day of trading, known as the average daily trading volume – ADTV). A high degree of volume indicates a lot of interest in a stock. Often, a boost in the volume of a stock is a harbinger of a price jump, either up or down.
Volatility is simply a measure of the predictable daily price range—the range in which a day trader operates. More volatility means greater profit or loss. After a recent check, Biocept Inc (NASDAQ: BIOC) stock is found to be 11.54% volatile for the week, while 12.52% volatility is recorded for the month.
The stock has a market cap of $18.71M and the number of outstanding shares has been calculated 58.72M. Based on a recent bid, its distance from 20 days simple moving average is -1.72%, and its distance from 50 days simple moving average is -13.07% while it has a distance of -65.14% from the 200 days simple moving average. The company’s distance from 52-week high price is -85.85% and the current price is 22.25% away from 52-week low price. The company has Relative Strength Index (RSI 14) of 48.75 together with Average True Range (ATR 14) of 0.04.
Past 5 years growth of BIOC observed at 35.10%, and for the next five years the analysts that follow this company is expecting its growth at 40.00%. The stock’s price to sales ratio for trailing twelve months is 3.46 and price to book ratio for the most recent quarter is 2.28, whereas price to cash per share for the most recent quarter are 3.17. Its quick ratio for the most recent quarter is 1.30. Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Disclaimer: Any news, report, research, and analysis published on Alphabetastock.com are only for information purposes. Alpha Beta Stock (ABS) makes sure to keep the information up to date and correct, but we didn’t suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. Information in this release is fact checked and produced by competent editors of Alpha Beta Stock; however, human error can exist.
This post was originally published on *this site*